Empagliflozin or dapagliflozin to prevent poor blood flow after heart attack stenting
Tests whether empagliflozin or dapagliflozin helps blood flow in heart attack patients having stenting.
Plain-language title generated from the registry record
Registry title: Evaluating SGLT2 Inhibitors for the Reduction of No-Reflow Phenomenon in Patients Undergoing PCI
Key facts
- Where
- Cairo, EgyptSee the 4 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07898709, who can take part
Where in Egypt
- Al-Hussein University HospitalCairo, EgyptNo longer taking part
- Al-Zahraa University HospitalCairo, EgyptNo longer taking part
- Islamic Cardiac Surgery Center , Al-Azhar UniversityCairo, EgyptNo longer taking part
- Sayed Galal University HospitalCairo, EgyptNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Al-Azhar University
- Trial code
- NCT07898709
- Record updated
- 27 October 2026
- Original description
Study Background \& Purpose:Read full original descriptionShow less
Evaluation of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Administration as Adjunctive Therapies for the Reduction of the No-reflow Phenomenon in Patients With Myocardial Infarction Undergoing Percutaneous Coronary Intervention (PCI): A Randomized Controlled Trial
Study Background \& Purpose:
The no-reflow phenomenon is a significant complication occurring in patients with acute myocardial infarction who undergo percutaneous coronary intervention (PCI). It leads to poor myocardial perfusion despite successful opening of the culprit coronary artery. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have demonstrated cardioprotective mechanisms beyond glucose control.
Objective:
This randomized controlled trial aims to evaluate the effectiveness and safety of administering SGLT2 inhibitors as adjunctive therapy in reducing the incidence of the no-reflow phenomenon in patients with myocardial infarction undergoing PCI.
Study Plan:
Eligible patients presenting with myocardial infarction scheduled for PCI will be randomized into three groups: one group receiving standard pharmacological care plus Empagliflozin therapy, second group receiving standard pharmacological care plus dapagliflozin therapy, and the control group receiving standard pharmacological care alone. Patients will be monitored during and after the procedure to evaluate coronary blood flow and incidence of no reflow phenomenon.
Inclusion: Adult male or female patients aged 18-75 years; Confirmed acute myocardial infarction; Will undergo percutaneous coronary intervention (PCI); Ability to receive the study medication before PCI without delaying the clinically indicated procedure; Ability and willingness to provide written informed consent and comply with the study protocol.
Exclusion: Ongoing treatment with SGLT2 inhibitors; Current Participation in another clinical trial or having participated in the week prior to recruitment; History of coronary artery bypass graft surgery; Known allergy to SGLT2 inhibitors; Severe hepatic impairment; Type 1 diabetes mellitus or history of diabetic ketoacidosis; Active infection or recurrent urinary/genital infections; Severe dehydration or clinical condition predisposing to volume depletion; For women of childbearing age:; Patients meeting any of the following criteria will be excluded:; Hemodynamically unstable patients(systolic blood pressure <90 mmHg or mean arterialpressure < 60 mmHg); Acute kidney injury or estimated glomerular filtration rate <30 mL/min/1.73 m²; Current or planned pregnancy or lactation.